Anthracyclines in Multidrug Resistant Lung Cancer
Author Information
Author(s): H.M. Coley, P. Workman, P.R. Twentyman
Primary Institution: MRC Clinical Oncology and Radiotherapeutics Unit, MRC Centre, Cambridge, UK
Hypothesis
Can anthracyclines retain activity in a multidrug resistant lung cancer cell line that does not express P-glycoprotein?
Conclusion
The study found that certain anthracyclines can remain effective against a multidrug resistant lung cancer cell line despite the absence of P-glycoprotein.
Supporting Evidence
- The COR-L23/R cell line shows cross-resistance to several drugs but not to modified anthracyclines.
- Verapamil did not significantly sensitize the COR-L23/R cell line.
- Reduced accumulation of doxorubicin was observed in the resistant cell line compared to the parental line.
- Energy-dependent efflux of daunorubicin was enhanced in the resistant cell line.
Takeaway
Some cancer cells can become resistant to drugs, but certain modified drugs can still work against them. This study shows that some anthracyclines can be effective even when the usual resistance mechanism is not present.
Methodology
The study involved creating a drug-resistant cell line and testing the effectiveness of various anthracyclines and resistance modifiers.
Limitations
The study primarily focuses on a single cell line, which may not represent all types of multidrug resistance in cancer.
Want to read the original?
Access the complete publication on the publisher's website